DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma. (Q54375138)
Jump to navigation
Jump to search
scientific article published on 24 February 2014
Language | Label | Description | Also known as |
---|---|---|---|
English | DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma. |
scientific article published on 24 February 2014 |
Statements
DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma. (English)
A Gupta
S Love
A Schuh
M Shanyinde
J M Larkin
R Plummer
P D Nathan
S Danson
L Collins
A Wise
R Asher
R Lisle
M R Middleton
24 February 2014
25
5
968-974
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference